The licence drug policy of the Medical Drug Agency. Permitted use in special needs
Rastad, J.A.; Klintberg, K.; Von Bahr, C.
Lakartidningen 93(47): 4309-4310
1996
ISSN/ISBN: 0023-7205 PMID: 8984304 Document Number: 466207
Document emailed within 1 workday
Related Documents
Bergen-Cico, D 2013: Perspectives of U.S. Drug Policy: Observations and Advice From Drug Policy Administrators in Emerging Democracies in Central and Eastern Europe World Medical and Health Policy 5(4): 362-388Panvichian, R.; Orth, K.; Day, M.L.; Day, K.C.; Pilat, M.J.; Pienta, K.J. 1998: Paclitaxel-associated multimininucleation is permitted by the inhibition of caspase activation: a potential early step in drug resistance Cancer Research 58(20): 4667-4672
Kamya, M.R.; Bakyaita, N.N.; Talisuna, A.O.; Were, W.M.; Staedke, S.G. 2002: Increasing antimalarial drug resistance in Uganda and revision of the national drug policy Tropical Medicine and International Health: Tm and Ih 7(12): 1031-1041
Niaz, K. 2017: International drug control system and the United Nations General Assembly Special Session (UNGASS) on the world drug problem: an overview Eastern Mediterranean Health Journal 23(3): 143-149
Huttunen, M.O. 1998: On drugs, drug users and drug policy Duodecim; Laaketieteellinen Aikakauskirja 114(20): 2100-2102
Andersson, M.L.; Böttiger, Y.; Lindh, J.D.; Wettermark, B.; Eiermann, B. 2013: Impact of the drug-drug interaction database SFINX on prevalence of potentially serious drug-drug interactions in primary health care European Journal of Clinical Pharmacology 69(3): 565-571
Vongchak, T.; Kawichai, S.; Sherman, S.; Celentano, D.D.; Sirisanthana, T.; Latkin, C.; Wiboonnatakul, K.; Srirak, N.; Jittiwutikarn, J.; Aramrattana, A. 2005: The influence of Thailand's 2003 'war on drugs' policy on self-reported drug use among injection drug users in Chiang Mai, Thailand International Journal of Drug Policy 16(2): 115-121
Borenstein, D. 1971: The relative value of the medical staff versus addicts in the rehabilitation of the drug users in a drug abuse program Johns Hopkins Medical Journal 129(5): 290-297
Wynn, R.L. 2009: Phentolamine mesylate--an old medical drug becomes a new dental drug General Dentistry 57(3): 200-202
Stålsby, C.; Westerholm, B. 1987: Are drug advertisements of any informative value? Analysis of drug advertisements in the Swedish Medical Journal (Läkartidningen) and the Norwegian Medical Journal (Tidsskrift for Den norske laegeforening) during the first half of 1986 Tidsskrift for den Norske Laegeforening: Tidsskrift for Praktisk Medicin Ny Raekke 107(17-18): 1573-1577
Lindgren, K. 1981: Increase knowledge on drug purposes for new agency Vardfacket 5(2): 57
Wilson, P. 1989: Brookings dialogues on public policy. Toward a national policy on drug and aids testing Health Policy 13(3): 253-254
Ritter, A. 2011: Ensuring the policy relevance of population health research: experiences from the Drug Policy Modelling Program New South Wales Public Health Bulletin 22(1-2): 19-22
Schleifer, R.; Pol, L. 2017: International Guidelines on Human Rights and Drug Control: A Tool for Securing Women's Rights in Drug Control Policy Health and human rights 19(1): 253-261
Schwetz, B.A. 2001: U.S. Food and Drug Administration--a science-based regulatory agency Journal - Association of Official Analytical Chemists 84(1): 171-175
Wendo, C. 2001: Uganda's drug regulatory agency faces financial crisis Lancet 358(9280): 482
Nishikaze, O. 1975: Drug-drug interaction and drug-induced interference with clinical laboratory test procedures--chairman's introductory remarks Rinsho Byori. Japanese Journal of Clinical Pathology 23(2): 75
Ekman, A.; Eriksson, A.; Böttiger, Y.; Reis, M.; Person, K.; Pettersson Kymmer, U.; Wallerstedt, S. 2019: Preparing for the licence to prescribe in medical school - a questionnaire study on medical students professional confidence in the art of prescribing Lakartidningen 116
Matsuda, T. 1993: Antithrombotic drug (thrombolytic drug, anticoagulant, antiplatelet drug) Nihon Rinsho. Japanese Journal of Clinical Medicine 51 Suppl: 179-185
1999: Recommendations for drug treatment of type 2 diabetes (I). Normalizing glucose levels. French Agency for Health Product Safety Presse Medicale 28(28): 1527-1533